A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppression in vivo

• Главные авторы: Min You (Автор), Fentian Chen (Автор), Chao Yu (Автор), Yuanzhi Chen (Автор), Yue Wang (Автор), Xue Liu (Автор), Xueran Guo (Автор), Bing Zhou (Автор), Xin Wang (Автор), Boya Zhang (Автор), Mujin Fang (Автор), Tianying Zhang (Автор), Ping Yue (Автор), Yingbin Wang (Автор), Quan Yuan (Автор), Wenxin Luo (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2023-12-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Introduction: The effective and persistent suppression of hepatitis B surface antigen (HBsAg) in patients with chronic HBV infection (CHB) is considered to be a promising approach to achieve a functional cure of hepatitis B. In our previous study, we found that the antibody E6F6 can clear HBsAg thro...